Hillsborough, NJ, United States of America

Matthew Michael Kreilein

This inventor holds 18 USPTO granted patents, plus 6 CIPO patents and 7 EPO patents. Top assignees: Signal Pharmaceuticals, Inc., Celgene Corporation, Celgene Quanticel Research, Inc.. Active years: 2013-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Michael Kreilein. Retrieved from https://idiyas.com/inventor/matthew-michael-kreilein

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 83.3

CIPO Patents = 6

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 7.9

ph-index = 4

Forward Citations = 66(Granted Patents)

Location History:

Watchung, NJ (US) (2013 - 2016)
Hilsborough, NJ (US) (2016)
Hillsborough, NJ (US) (2015 - 2020)

Company Filing History:

10 out of 169

Signal Pharmaceuticals, Inc.

Celgene Quanticel Research, Inc.

patents

Years Active: 2013-2020

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10703739 - Compositions comprising an inhibitor of lysine specific demethylase-1 (2020-07-07),

2. 10590136 - Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide (2020-03-17),

3. 10513519 - Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use (2019-12-24),

4. 10316016 - Compositions comprising an inhibitor of lysine specific demethylase-1 (2019-06-11),

5. 10047090 - Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use (2018-08-14),

6. 10047069 - Compositions comprising an inhibitor of lysine specific demethylase-1 (2018-08-14),

7. 9974786 - [object Object] (2018-05-22),

8. 9828358 - Compositions comprising an inhibitor of lysine specific demethylase-1 (2017-11-28),

9. 9827243 - Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one (2017-11-28),

10. 9795603 - Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use (2017-10-24),

11. 9604939 - Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use (2017-03-28),

12. 9403829 - [object Object] (2016-08-02),

13. 9359364 - Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one (2016-06-07),

14. 9303014 - [object Object] (2016-04-05),

15. 9266858 - [object Object] (2016-02-23),

Title: The Innovative Contributions of Matthew Michael Kreilein

Introduction

Matthew Michael Kreilein is a prominent inventor based in Hillsborough, NJ (US). He has made significant contributions to the field of pharmaceuticals, holding a total of 18 patents. His work primarily focuses on developing inhibitors for specific enzymes that play a crucial role in various diseases.

Latest Patents

Kreilein's latest patents include compositions comprising an inhibitor of lysine specific demethylase-1. These patents describe both amorphous and crystalline forms of pharmaceutically acceptable salts of the lysine specific demethylase-1 inhibitor 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile. Additionally, he has developed pharmaceutical compositions suitable for administration to mammals, which include the lysine specific demethylase-1 inhibitor. These compositions are intended for treating diseases or conditions associated with lysine specific demethylase-1 activity. Another notable patent involves processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide.

Career Highlights

Throughout his career, Kreilein has worked with several notable companies, including Signal Pharmaceuticals, Inc. and Celgene Corporation. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Kreilein has collaborated with various professionals in his field, including Juan Antonio Gamboa and Benjamin Cohen. These collaborations have further enhanced his innovative work and expanded the impact of his inventions.

Conclusion

Matthew Michael Kreilein is a distinguished inventor whose work in pharmaceutical innovations has led to numerous patents and advancements in medical treatments. His contributions continue to influence the field and improve patient outcomes.

Profile summary based on public USPTO records.